載入...
Abemaciclib Improves Disease‐Free Survival in High‐Risk HR+/HER2– Early Breast Cancer
Abemaciclib is the first CDK 4/6 inhibitor to show a significant clinical benefit when added to adjuvant endocrine therapy in patients with high‐risk, node‐positive, HR‐positive, HER2‐negative, early‐stage breast cancer, according to findings from the phase III monarchE trial.
Na minha lista:
| 發表在: | Oncologist |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley & Sons, Inc.
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7869338/ https://ncbi.nlm.nih.gov/pubmed/33399254 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13665 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|